Talazoparib (Talzenna®) HTA ID: 19032
Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 19/08/2019 |
| Rapid review completed | 03/09/2019 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talazoparib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 09/09/2019 |
| Pre-submission consultation with Applicant | 02/12/2019 |
| Initial submission received from Applicant | 02/03/2020 |
| Complete submission received from Applicant | 06/03/2020 |
| Preliminary review sent to Applicant | 24/04/2020 |
| NCPE assessment re-commenced | 05/06/2020 |
| Factual accuracy sent to Applicant | 14/08/2020 |
| NCPE assessment re-commenced | 21/08/2020 |
| NCPE assessment completed | 18/09/2020 |
| NCPE assessment outcome | The NCPE recommends that talazoparib (Talzenna®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.